Safety and efficacy of daridorexant in the treatment of insomnia: a systematic review and meta-analysis of randomized controlled trials

被引：6

作者：

Albadrani, Muayad Saud

Albadrani, Muhannad Saud ^{[1
]}

Fadlalmola, Hammad Ali ^{[2
]}

Elhusein, Amal Mohamed ^{[3
]}

Abobaker, Randa Mohamed ^{[4
]}

Merghani, Magda Mubarak ^{[5
]}

Gomaa, Salma Mohammed ^{[5
]}

Abdalla, Abdalla Mohamed ^{[6
]}

Alhujaily, Muhanad ^{[7
]}

Omair, Altufayl Abdulrahman ^{[8
]}

Abdalla, Adel Mohamed Ali

Masada, Huda Khalafallah ^{[11
]}

Swamy, D. S. Veerabhadra ^{[9
]}

AL-Sayaghi, Khaled M. M. ^{[10
]}

机构：

[1] Taibah Univ, Coll Med, Dept Family & Community Med, Madinah, Saudi Arabia

[2] Taibah Univ, Nursing Coll, Dept Community Hlth Nursing, Medina, Saudi Arabia

[3] Univ Bisha, Coll Aappl Med Sci, Nursing Dept, Bisha, Saudi Arabia

[4] Gulf Coll, Hosp & Hlth Serv Adm Dept, Hafer Al Batin, Saudi Arabia

[5] Hafr Al Batin Univ, Coll Appl Med Sci, Nursing Dept, Hafar Al Batin, Saudi Arabia

[6] Najran Univ, Coll Nursing, Dept Community & Mental Hlth, Najran, Saudi Arabia

[7] Univ Bisha, Coll Appl Med Sci, Dept Clin Lab Sci, Bisha, Saudi Arabia

[8] Psychiat & Long Term Care Hosp PLTCH, Bisha, Saudi Arabia

[9] Univ Bisha, Coll Appl Med Sci, Nursing Dept, Bisha, Saudi Arabia

[10] Taibah Univ, Coll Nursing, Dept Med Surg Nursing, Al Madinah Al Munawarah, Saudi Arabia

[11] Northern Coll Nursing, Maternal & Child Hlth Nursing Dept, Riyadh, Saudi Arabia

来源：

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY | 2023年 / 38卷 / 01期

关键词：

daridorexant; efficacy; insomnia; meta-analysis; safety; systematic review; OREXIN RECEPTOR ANTAGONIST; SLEEP; SUVOREXANT; PROFILE;

D O I：

10.1097/YIC.0000000000000425

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Daridorexant is a novel dual orexin receptor antagonist used in treating insomnia disorder. Daridorexant improves sleep quality without impairing daytime functioning. We assess the safety and efficacy of this novel drug in the treatment of insomnia. We performed a systematic search for electronic databases in SCOPUS, PubMed, Web of Science and the Cochrane library. Seven randomized controlled trials were included in this review, with 2425 participants enrolled. Daridorexant was superior to placebo in reducing wake time after sleep onset (MD = -13.26; 95% CI, -15.48 to -11.03; P < 0.00001), latency to persistent sleep (MD = -7.23; 95% CI, -9.60 to -4.85; P < 0.00001), with increasing the total sleep time (MD = 14.80; 95% CI, 11.18-18.42; P < 0.00001) and subjective total sleep time (MD = 14.80; 95% CI, 11.18-18.42], P < 0.00001). The 25 mg and 50 mg were the most officious doses. Treatment with daridorexant has resulted in a slightly higher incidence of adverse events [risk ratio (RR) = 1.19; 95% CI, 1.05-1.35;, P = 0.005], specifically somnolence (RR = 1.19; 95% CI, 1.13-3.23; P = 0.005) and fatigue (RR = 2.01; 95% CI, 1.21-3.36; P = 0.007). Daridorexant is superior to placebo in improving sleep quality. However, the drug resulted in a slightly higher incidence of adverse events, including somnolence and fatigue.

引用

页码：57 / 65

页数：9

共 30 条

[21] Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia [J].